Ustekinumab serum concentrations are associated with clinical outcomes in Crohn's disease - a regional multi-center pilot study.

CONCLUSION:  Trough concentrations of UST 8 weeks after induction predict clinical response to therapy in week 16 with moderate sensitivity and specificity. TDM using LC-MSMS could prove beneficial in personalized UST therapy of patients with CD by identifying individuals with subtherapeutic concentrations who might benefit from dose escalation.
PMID: 32045954 [PubMed - as supplied by publisher]

Source: Zeitschrift fur Gastroenterologie - February 10, 2020 Category: Gastroenterology Authors: Thomann AK, Schulte LA, Globig AM, Hoffmann P, Klag T, Itzel T, Teufel A, Schreiner R, Scheffe N, Ebert MP, Wehkamp J, Gauss A, Hasselblatt P, Klaus J, Reindl W Tags: Z Gastroenterol Source Type: research